In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda (TYO: 4502) has made the decision unanimously to appoint Julie Kim as the successor to Christophe Weber, Takeda’s president, chief executive (CEO) and representative director, when Mr Weber retires from the company in June 2026.
Mr Kim is currently president of Takeda’s US Business Unit, and will be proposed as a candidate for election to the board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr. Weber will not hold a board seat after retiring from Takeda.
“The board of directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said Masami Iijima, chairman of the board of directors meeting and of the Nomination Committee.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze